Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $361.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 9.39% from the stock’s previous close.

Other analysts have also issued research reports about the stock. TD Cowen lifted their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Citigroup upped their price target on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Royal Bank Of Canada initiated coverage on Krystal Biotech in a research note on Friday, August 14th. They issued an “outperform” rating and a $400.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on Krystal Biotech in a research note on Thursday, September 24th. They issued a “buy” rating and a $441.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $377.20.

Krystal Biotech Stock Down 0.2%

KRYS traded down $0.69 during trading on Thursday, reaching $330.00. The company’s stock had a trading volume of 283,868 shares, compared to its average volume of 327,922. The firm has a fifty day simple moving average of $340.46 and a two-hundred day simple moving average of $322.60. Krystal Biotech has a 1 year low of $183.03 and a 1 year high of $382.54. The company has a market cap of $9.77 billion, a price-to-earnings ratio of 41.35 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, equities analysts forecast that Krystal Biotech will post 7.47 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. Hsbc Holdings PLC purchased a new stake in shares of Krystal Biotech during the second quarter worth $3,653,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Krystal Biotech during the second quarter worth $3,865,000. Bank of America Corp DE increased its position in shares of Krystal Biotech by 36.6% during the first quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after acquiring an additional 69,840 shares during the period. Assetmark Inc. purchased a new stake in shares of Krystal Biotech during the first quarter worth $816,000. Finally, Corient Private Wealth LP increased its position in shares of Krystal Biotech by 767.4% during the second quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock worth $11,357,000 after acquiring an additional 27,035 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.